Diabetes Board decisions

The Board denied an initial compensable rating for pseudofolliculitis barbae and remanded the claims for service connection for hypertension, diabetes adult-onset, eye condition/vision, high cholesterol, bilateral hearing loss, and right knee condition.

The Board denied service connection for all claimed conditions as the evidence of record does not support a finding that any diagnosed condition is related to the Veteran's active duty service or to a service-connected disability.

The Board denied an initial rating in excess of 20 percent for Type II diabetes mellitus and granted an effective date of August 10, 2022, for the award of service connection.

The Board remands the claims for service connection for various conditions, including heart disorder, hypertension, stroke, diabetes, lumbosacral strain, cold weather injuries, sinusitis, degenerative arthritis, and an acquired psychiatric disorder, to obtain a TERA memorandum and appropriate medical examinations.

The Board remands the claims for service connection for diabetes mellitus and hypertension for readjudication based on new and relevant evidence.

The Board denied service connection for diabetes mellitus and remanded the claims for left knee strain and right knee strain.

The Board denied a total disability rating based on individual unemployability (TDIU) before December 27, 2011, and an earlier effective date for the grant of basic eligibility to Dependents Educational Assistance (DEA).

The Board denied the Veteran's claim for an increased rating for his service-connected diabetes mellitus, type II.

The Board granted service connection for headaches as a residual of a head injury, but remanded the claims for obstructive sleep apnea (OSA), type II diabetes mellitus (diabetes), hypertension, and entitlement to a total disability rating based on individual unemployability (TDIU) prior to May 10, 2022.

The Veteran withdrew his appeal, and the Board dismissed all issues.

The Board remands the claims for a recurrent left hip disability and Type II diabetes mellitus to ensure that there is a complete record upon which to decide the claims.

The Board granted service connection for diabetes mellitus and coronary artery disease (CAD) as secondary to herbicide exposure, but denied service connection for left and right upper extremity neuropathy.

The Board granted service connection for tinnitus and remanded the claims for service connection for an acquired psychiatric disorder, posttraumatic stress disorder, type II diabetes mellitus, right lower extremity peripheral neuropathy, and hypertension.

The Board remands the claims for service connection for type II diabetes mellitus, hypertension, and a TDIU due to an inadequate medical opinion regarding the etiology of these conditions.

The Board denied service connection for hypertension, arteriosclerotic heart disease (coronary artery disease), and type 2 diabetes mellitus as there was no evidence of exposure to Agent Orange or other herbicides during the Veteran's service in Okinawa.

The Board remands the claims for service connection for diabetes mellitus and low back disability to correct duty-to-assist errors that occurred prior to the March 2023 decision on appeal.

The Board denied increased ratings for PTSD, diabetes mellitus, type II, and hypothyroidism while granting increased ratings for peripheral neuropathy in the right and left lower extremities, hearing loss (left ear), and a compensable evaluation for scars, burns (2nd degree).

The Board denied the Veteran's claims for increased ratings and service connection, finding that the evidence did not support higher ratings or service connection.

The Board denied the Veteran's claim for an initial disability rating in excess of 20 percent for service-connected diabetes mellitus, type II, as the probative evidence did not establish that his diabetes required one or more daily injections of insulin, a restricted diet, and regulation of activities.

The Board granted service connection for polyuria, erectile dysfunction associated with diabetes mellitus, and loss of use of both feet, as well as an initial rating of 50 percent for migraine headaches.